(Q36415110)

14 August 2017

1 reference

title

The application of epigenetic modifiers on the treatment of prostate and bladder cancer (English)

1 reference

14 August 2017

Zhengwang Zhang

1

1 reference

14 August 2017

Jose Karam

2

1 reference

14 August 2017

Eugene Frenkel

3

1 reference

14 August 2017

Arthur Sagalowsky

4

1 reference

14 August 2017

Jer-Tsong Hsieh

5

1 reference

14 August 2017

publication date

1 March 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

24

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

152-160

1 reference

Epigenetics: regulation through repression

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Transcription factor-specific requirements for coactivators and their acetyltransferase functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

The CBP co-activator is a histone acetyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Gene silencing in cancer in association with promoter hypermethylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Hypermethylation of CpG islands in primary and metastatic human prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

DNA hypermethylation status of multiple genes in prostate adenocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

14-3-3sigma is down-regulated in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Multiple mechanisms downregulate CDKN1C in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

A quantitative promoter methylation profile of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Frequent hypermethylation of the RASSF1A gene in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Altered methylation of multiple genes in carcinogenesis of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Frequent hypermethylation of promoter region ofRASSF1A in tumor tissues and voided urine of urinary bladder cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Hypermethylation of tumor-related genes in genitourinary cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

DNA methylation in the androgen receptor gene promoter region in rat prostate cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Endothelin B receptor gene hypermethylation in prostate adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Hypermethylation of the caveolin-1 gene promoter in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

MT1G hypermethylation is associated with higher tumor stage in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Neutral endopeptidase protein expression and prognosis in localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

PMP24, a gene identified by MSRF, undergoes DNA hypermethylation-associated gene silencing during cancer progression in an LNCaP model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

The DNA methyltransferases of mammals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

The human Dnmt2 has residual DNA-(cytosine-C5) methyltransferase activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Deoxyribonucleic acid methyltransferase from the eukaryote, Chlamydomonas reinhardi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Mammalian (cytosine-5) methyltransferases cause genomic DNA methylation and lethality in Drosophila.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Histone deacetylase and DNA methyltransferase in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

DNA methyltransferase and demethylase in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Crystal structure of the nucleosome core particle at 2.8 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Chromatin Structure: A Repeating Unit of Histones and DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Chromatin-modifying and -remodeling complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Transcriptional activation of p21(WAF1/CIP1) by apicidin, a novel histone deacetylase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

DNA methyltransferase inhibitors-state of the art.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

High-performance Liquid Chromatographic Analysis of Chemical Stability of 5-aza-2′-Deoxycytidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Cellular differentiation, cytidine analogs and DNA methylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Histone deacetylase inhibitors: from target to clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Butyrate as a differentiating agent: pharmacokinetics, analogues and current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Preclinical antitumor activity of CI-994.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Preclinical toxicity of a new oral anticancer drug, CI-994 (acetyldinaline), in rats and dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Modulation of radiation response by histone deacetylase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Evaluation of antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Psammaplins from the Sponge Pseudoceratina purpurea: Inhibition of Both Histone Deacetylase and DNA Methyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

The polycomb group protein EZH2 is involved in progression of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.004

10.1016/J.UROLONC.2005.11.004

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference